Contact Information: At RegeneRx: At the Financial |
RegeneRx Adds Dr. Paolo Carminati to Medical and Scientific Advisory Board RegeneRx Adds Dr. Paolo Carminati to Medical and Scientific Advisory Board June 10, 2004 — Bethesda, Md RegeneRx Biopharmaceuticals, Inc. (OTCBB:RGRX) (www.regenerx.com) announced the addition of Dr. Paolo Carminati to its Medical and Scientific Advisory Board (MSAB). Dr. Carminati is Director of Research and Development at Sigma-Tau Group, a pharmaceutical firm headquartered in Rome, Italy. Sigma-Tau, through its wholly owned subsidiary, Defiante Farmaceutica Lda, is the exclusive European licensee for RegeneRx’s Thymosin beta 4 (Tß4) for the treatment of internal and external wounds. Dr. Paolo Carminati has extensive experience in managing pharmaceutical R&D in industrial contexts, having directed over his career the research and development at Midy-Sanofi, Farmitalia Carlo Erba and Serono. He is also a member of the Board of Directors of several of Sigma-Tau Group’s companies, including as President of Sigma-Tau Research, Inc., a company devoted to clinical development of its products in the U.S., and as Chairman of the Board and President at Tecnogen, the Group’s biotech company specializing in the production of monoclonal antibodies and recombinant proteins. Dr. Carminati is a member of a number of prestigious European and American scientific societies. He has authored 150 abstracts and 70 full papers, and is a co-inventor on 40 patents. “We are very pleased that Dr. Carminati has agreed to serve on our Medical and Scientific Advisory Board,” said Dr. Allan Goldstein, chairman of the MSAB. “Dr. Carminati brings substantial scientific and pharmaceutical expertise that ranges from research and development through clinical trials and the development of new drugs. His presence also indicates the commitment of Sigma-Tau to our effort. We look forward to his input and guidance as we continue to develop our technology platform.” RegeneRx’s Medical and Scientific Advisory Board consists of experts in various medical and scientific fields who advise the Company on key aspects of its wound-healing technology platform, which is based on Thymosin beta 4. They advise the Company in such areas as potential therapeutic uses for Tß4, strategies for clinical development, and evaluation of new scientific or medical data. The MASB is headed by Dr. Allan Goldstein, RegeneRx’s Chairman and Chief Scientific Advisor. Tß4 is a naturally occurring 43-amino acid peptide present in virtually all human cells. It represents a new class of wound healing drug and is different from other wound repair factors, such as growth factors, in that it promotes endothelial cell differentiation and keratinocyte cell migration, down-regulates a number of inflammatory cytokines and chemokines, and has a very low molecular weight, allowing it to diffuse relatively long distances through tissues. A key mechanism of action is Tß4’s ability to regulate the cell-building protein, actin, a vital component of the cytoskeleton. Additionally, it has recently been reported that Tß4 directly influences the production of laminin-5, a protein necessary for proper adhesion of certain types of mammalian cells and an important component of the wound healing process. Tß4 has been the subject of a significant amount of research at the NIH and a number of other academic institutions, and has been reported to be effective in the repair of dermal and corneal wounds in numerous animal models under a variety of conditions. RegeneRx is a biopharmaceutical company developing Tß4 as a platform technology for the treatment of acute and chronic wounds and for the treatment of a variety of human diseases involving tissue and organ repair under an exclusive world-wide license from the NIH. The Company holds several patents related to the technology and has numerous world-wide patent applications pending. RegeneRx successfully completed Phase I human clinical trials with Tß4 for the treatment of chronic dermal wounds and expects Phase II trials to begin shortly. The information in this press release may include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including the ongoing and prospective development of Tß4 and possible future benefits to the Company, its shareholders, and patients. Due to the nature of product development and the regulatory approval process, the forward-looking statements are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-KSB. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company. |
